Most powerful obesity drug yet: People lost up to 25% of weight in trial
Eli Lilly's experimental obesity drug retatrutide has shown significant weight loss results in clinical trials, with patients losing up to 25% of their body weight. The drug, a triple-hormone receptor agonist, targets GLP-1, GIP, and glucagon receptors. In trials, patients with type 2 diabetes and obesity lost an average of 20-23.3% of their body weight. The drug also improved blood sugar control and reduced inflammation.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Retatrutide is a triple-hormone obesity drug simulating GLP-1, GIP, and glucagon.
- ✓ Patients lost up to 25% of their body weight in trials.
- ✓ The drug improved blood sugar control and reduced inflammation.
- ✓ Retatrutide targets three metabolic receptors: GLP-1, GIP, and glucagon.
What changed
New trial data shows Eli Lilly's retatrutide achieves up to 25% weight loss, surpassing previous results.
Live updates
-
Eli Lilly's retatrutide shows up to 25% weight loss in trials
Eli Lilly's experimental obesity drug retatrutide has shown significant weight loss results in clinical trials, with patients losing up to 25% of their body weight. The drug, a triple-hormone receptor agonist, targets GLP-1, GIP, and glucagon receptors. In trials, patients with type 2 diabetes and obesity lost an average of 20-23.3% of their body weight. The drug also improved blood sugar control and reduced inflammation.
Why it matters
The obesity drug market is highly competitive, with several pharmaceutical companies developing new treatments. Retatrutide's promising results could make it a leading contender. Obesity is a major public health concern, with limited treatment options available. Effective treatments could have significant impacts on patients' health and quality of life.
What is confirmed
- Retatrutide is a triple-hormone obesity drug simulating GLP-1, GIP, and glucagon.
- Patients lost up to 25% of their body weight in trials.
- The drug improved blood sugar control and reduced inflammation.
- Retatrutide targets three metabolic receptors: GLP-1, GIP, and glucagon.
- Patients with type 2 diabetes and obesity lost an average of 20-23.3% of their body weight.
Still unconfirmed
- Eli Lilly's retatrutide could be submitted to the FDA for approval early next year.
What to watch next
- FDA approval decision
- Phase 3 trial results publication
- Comparative trials with other obesity drugs
confidence 95%Sources used for this update (18)
- Ars Technica — Most powerful obesity drug yet: People lost up to 25% of weight in trial
- The Guardian — ‘Godzilla’ of weight-loss drugs could provide other important health benefits
- Reuters — Lilly's experimental drug cuts weight by 21% in diabetes trial
- Scientific American — Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs
- NBC News — People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug
- www.theguardian.com — ‘Godzilla’ of weight-loss drugs could provide other important ...
- arstechnica.com — Most powerful obesity drug yet: People lost up to 25% of ...
- www.everydayhealth.com — Retatrutide Led to Significant Weight Loss in Newly Published Diabetes Trial - Everyday Health
- medicalxpress.com — New investigational drug delivers up to 23.3% weight loss in people with obesity and diabetes
- time.com — Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results
- www.prnewswire.com — Lilly's triple agonist, retatrutide, delivered substantial ...
- www.fool.com — Lilly Just Reported More Than Half of Patients on Its New ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community